These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 14555232

  • 1. The histone deacetylase inhibitor suberic bishydroxamate: a potential sensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis.
    Zhang XD, Gillespie SK, Borrow JM, Hersey P.
    Biochem Pharmacol; 2003 Oct 15; 66(8):1537-45. PubMed ID: 14555232
    [Abstract] [Full Text] [Related]

  • 2. Bim plays a crucial role in synergistic induction of apoptosis by the histone deacetylase inhibitor SBHA and TRAIL in melanoma cells.
    Gillespie S, Borrow J, Zhang XD, Hersey P.
    Apoptosis; 2006 Dec 15; 11(12):2251-65. PubMed ID: 17051334
    [Abstract] [Full Text] [Related]

  • 3. The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells.
    Zhang XD, Gillespie SK, Borrow JM, Hersey P.
    Mol Cancer Ther; 2004 Apr 15; 3(4):425-35. PubMed ID: 15078986
    [Abstract] [Full Text] [Related]

  • 4. Sensitization of mesothelioma to TRAIL apoptosis by inhibition of histone deacetylase: role of Bcl-xL down-regulation.
    Neuzil J, Swettenham E, Gellert N.
    Biochem Biophys Res Commun; 2004 Jan 30; 314(1):186-91. PubMed ID: 14715264
    [Abstract] [Full Text] [Related]

  • 5. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
    Zhang XD, Wu JJ, Gillespie S, Borrow J, Hersey P.
    Clin Cancer Res; 2006 Feb 15; 12(4):1355-64. PubMed ID: 16489094
    [Abstract] [Full Text] [Related]

  • 6. Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio.
    Mühlethaler-Mottet A, Flahaut M, Bourloud KB, Auderset K, Meier R, Joseph JM, Gross N.
    BMC Cancer; 2006 Aug 24; 6():214. PubMed ID: 16930472
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL.
    Butler LM, Liapis V, Bouralexis S, Welldon K, Hay S, Thai le M, Labrinidis A, Tilley WD, Findlay DM, Evdokiou A.
    Int J Cancer; 2006 Aug 15; 119(4):944-54. PubMed ID: 16550602
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. TNF-related apoptosis-inducing ligand-induced apoptosis of melanoma is associated with changes in mitochondrial membrane potential and perinuclear clustering of mitochondria.
    Thomas WD, Zhang XD, Franco AV, Nguyen T, Hersey P.
    J Immunol; 2000 Nov 15; 165(10):5612-20. PubMed ID: 11067917
    [Abstract] [Full Text] [Related]

  • 13. Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation.
    Rosato RR, Dai Y, Almenara JA, Maggio SC, Grant S.
    Leukemia; 2004 Nov 15; 18(11):1780-8. PubMed ID: 15385934
    [Abstract] [Full Text] [Related]

  • 14. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by smac/DIABLO release from mitochondria.
    Zhang XD, Zhang XY, Gray CP, Nguyen T, Hersey P.
    Cancer Res; 2001 Oct 01; 61(19):7339-48. PubMed ID: 11585775
    [Abstract] [Full Text] [Related]

  • 15. Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells.
    Rosato RR, Almenara JA, Dai Y, Grant S.
    Mol Cancer Ther; 2003 Dec 01; 2(12):1273-84. PubMed ID: 14707268
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.